

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/180565 A1

(51) International Patent Classification:

A61K 9/19 (2006.01) *A61K 47/40* (2006.01)
A61K 9/08 (2006.01) *A61P 35/00* (2006.01)
A61K 31/198 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/EP2023/057729

(22) International Filing Date:

24 March 2023 (24.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2204171.9 24 March 2022 (24.03.2022) GB

(71) Applicant: **ONCOPEPTIDES AB** [SE/SE]; Luntmakargatan 46, 7th Floor, 111 37 Stockholm (SE).

(72) Inventors: **LEHMANN, Fredrik**; c/o Oncopeptides AB, Västra Trädgårdsgatan 15, 111-53 Stockholm (SE). **TEODOROVIC, Peter**; c/o Oncopeptides AB, Västra Trädgårdsgatan 15, 111-53 Stockholm (SE). **HAMMER, Kristin**; c/o Oncopeptides AB, Västra Trädgårdsgatan 15, 111-53 Stockholm (SE). **RINGOM, Rune**; c/o Recipharm OT Chemistry AB, Virdings allé 16, 754-50 Uppsala (SE).

(74) Agent: **ABEL & IMRAY**; Westpoint Building, James Street West, Bath Bath and North East Somerset BA1 2DA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN

(57) Abstract: The invention provides a pharmaceutical preparation comprising melphalan flufenamide, or a salt thereof, and γ -cyclodextrin or a pharmaceutically acceptable derivative of γ -cyclodextrin. The invention further provides compositions comprising the pharmaceutical preparation of the invention, and kits and uses of the pharmaceutical preparations of the invention.

WO 2023/180565 A1